Seres Therapeutics (MCRB) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research • 11/04/26
Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)GlobeNewsWire • 11/04/26
Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation RecipientsGlobeNewsWire • 11/03/26
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026GlobeNewsWire • 10/15/26
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/08/26
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire • 09/01/26
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities CostsGlobeNewsWire • 08/05/26
Seres Therapeutics' SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity StudyMarketBeat • 07/10/26
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis TranscriptSeeking Alpha • 07/08/26
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer TreatmentGlobeNewsWire • 07/08/26
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related EnterocolitisGlobeNewsWire • 06/25/26
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027GlobeNewsWire • 06/05/26
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor ConferenceGlobeNewsWire • 05/12/26
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/05/26
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel DiseaseGlobeNewsWire • 05/04/26
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026GlobeNewsWire • 04/20/26
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewsWire • 03/12/26
Seres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome Therapeutics Platform Prepared Remarks TranscriptSeeking Alpha • 03/03/26
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business UpdatesGlobeNewsWire • 03/02/26
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune DiseasesGlobeNewsWire • 02/12/26
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic StrategyGlobeNewsWire • 01/06/26